Although the increased risk of infections with some disease-modifying drugs (DMDs) is known, we still lack sufficient real-world clinical data to evaluate and compare the risk levels of individual drugs. A Swedish study therefore provides information about these risks with glatiramer acetate, beta interferon, natalizumab, fingolimod, and rituximab in the treatment of multiple sclerosis (MS).
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
